Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    NCT01553916
Previous Study | Return to List | Next Study

Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Washington University School of Medicine
Information provided by (Responsible Party):
Washington University School of Medicine Identifier:
First received: March 12, 2012
Last updated: January 26, 2017
Last verified: January 2017
This phase I/II trial studies the effects and safety of giving lithium carbonate (lithium) to patients with small cell lung cancer (SCLC) undergoing radiation therapy to the brain (PCI; prophylactic cranial irradiation). PCI is used to prevent cancer metastases from returning in the brain. This treatment can cause short-term memory problems by damaging the hippocampus. Lithium may help prevent or lessen memory problems caused by PCI by protecting the hippocampus.

Condition Intervention Phase
Small Cell Lung Carcinoma
Drug: Lithium Carbonate
Radiation: Prophylactic cranial irradiation
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Supportive Care
Official Title: Phase I/II Trial of Lithium as a Neuroprotective Agent for Patients With Small Cell Lung Cancer (SCLC) Treated With Prophylactic Cranial Irradiation (PCI)

Resource links provided by NLM:

Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • Dose-limiting toxicities of lithium (DLTs), (safety lead-in) [ Time Frame: 3 weeks ]
    Graded and described using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4. Safety will be defined as < 2 patients experiencing DLTs of the first 6 treated.

  • Rate of immediate recall memory deterioration at 3 months, (phase II) [ Time Frame: 3 months ]
    Proportion of patients with deterioration defined as a drop from the HVLT-IR baseline test score that is greater than or equal to the reliable change index (RCI).

Secondary Outcome Measures:
  • Rate of immediate recall memory deterioration at 6 and 12 months [ Time Frame: 12 months ]
    Proportion of patients with deterioration, defined as a drop from the HVLT-IR baseline test score that is greater than or equal to the reliable change index (RCI).

  • Rate of delayed recall memory deterioration at 3, 6 and 12 months [ Time Frame: 12 months ]
    The percentage of patients with a decrease in HVLT-DR test score compared to baseline.

  • Incidence of brain metastases [ Time Frame: 12 months ]
    1-year rate of brain metastases together with 95% confidence interval will be calculated based on Kaplan-Meier curve.

  • Overall survival [ Time Frame: 12 months ]
    Median and 1-year rate of overall survival together with 95% confidence interval will be calculated based on Kaplan-Meier curve.

  • Changes in quality-of-life following PCI [ Time Frame: 12 months ]
    Assessed by comparing questionnaire test scores to baseline; European Organization for Research and Treatment of Cancer (EORTC) QLQ30 (global health/QOL, cognitive functioning, and fatigue scales) and BN20 (future uncertainty and communications deficit scales)

  • Change in hippocampal morphology following lithium + PCI [ Time Frame: 12 months ]
    Hippocampal volume, surface area, and length will be measured using a standardized imaging protocol (magnetization prepared rapid acquisition gradient echo; MPRAGE)

  • Incidence of adverse events [ Time Frame: 30 days after completion of therapy ]
    Adverse events will be tabulated by type and grade using NCI CTCAE v 4.

  • Feasibility of performing serial neurocognitive testing and quality of life exams in patients wit [ Time Frame: 12 months ]
    Defined as at least 4 of 6 patients successfully completing pre-treatment and 3 month post-treatment testing

Estimated Enrollment: 26
Actual Study Start Date: April 26, 2012
Estimated Study Completion Date: October 31, 2018
Estimated Primary Completion Date: October 31, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1

Lithium carbonate 300 mg PO BID for 7 days prior to the start of prophylactic cranial irradiation (PCI) and will be continued during PCI.

PCI will be given at 2.5 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 25 Gy, starting on Day 8 after 7 days of lithium.

Drug: Lithium Carbonate
Other Name: Eskalith, Lithane, Lithium, Lithobid, Lithonate, Lithotabs
Radiation: Prophylactic cranial irradiation
Other Name: PCI


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient must have histologically or cytologically confirmed small cell lung cancer. Patients with either limited or extensive stage disease are eligible.
  • Patient must have completed 4-6 cycles of platinum-based chemotherapy (+/- thoracic radiotherapy).
  • Patient must have no evidence of progressive disease on restaging imaging within 3 months of enrollment
  • For patients taking medications known to have a significant interaction with lithium carbonate, these medications should be discontinued at least 1 week prior to and during lithium treatment
  • Patient must be > or = 18 years old.
  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
  • Leukocytes >= 3,000/mcL
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 3.0 x IULN
  • Creatinine within normal institutional limits OR creatinine clearance >= 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
  • Patient must have an electrocardiogram without evidence of arrhythmia, QT prolongation (QTc > 450 ms in males and > 470 ms in females), or other severe dysfunction within 2 weeks of initiation of lithium
  • Women of childbearing potential (women with regular menses, women with amenorrhea, women with irregular cycles, women using a contraceptive method that precludes withdrawal bleeding, and women who have had a tubal ligation) are required to have a negative urine pregnancy test within 14 days prior to the first dose of lithium.
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
  • Patient (or legally authorized representative if applicable) must be able to understand and willing to sign an Internal Review Board (IRB) approved written informed consent document

Exclusion Criteria:

  • Patient must not have history of prior cranial radiotherapy
  • Patient must not have brain metastases present prior to initiation of initial therapy or PCI
  • Patient must not have evidence of progressive disease
  • Patient must not have received chemotherapy within 3 weeks of initiation of PCI
  • Patient must not have a history of other malignancy =< 2 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix
  • Patient must not be actively receiving any other investigational agents
  • Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to lithium carbonate
  • Patient must not have any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patient must not have any uncontrolled thyroid disease
  • Patient must not have a seizure disorder
  • Patient must not be pregnant and/or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01553916

Contact: Clifford Robinson, M.D. 314-362-4633

United States, Missouri
Washinton University School of Medicine Recruiting
St. Louis, Missouri, United States, 63110
Contact: Clifford Robinson, M.D.    314-362-4633   
Principal Investigator: Clifford Robinson, M.D.         
Sub-Investigator: Dinesh Thotala, Ph.D.         
Sub-Investigator: Jeffrey Bradley, M.D.         
Sub-Investigator: Todd DeWees, Ph.D.         
Sub-Investigator: Tammie Benzinger, M.D.         
Sub-Investigator: Daniel Marcus, Ph.D.         
Sub-Investigator: Dennis Hallahan, M.D.         
Sponsors and Collaborators
Washington University School of Medicine
Principal Investigator: Clifford Robinson, M.D. Washington University School of Medicine
  More Information

Additional Information:
Responsible Party: Washington University School of Medicine Identifier: NCT01553916     History of Changes
Other Study ID Numbers: 201202073
Study First Received: March 12, 2012
Last Updated: January 26, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Small Cell Lung Carcinoma
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Lithium Carbonate
Neuroprotective Agents
Antidepressive Agents
Psychotropic Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Protective Agents processed this record on April 28, 2017